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ABSTRACT
Long-term survival still eludes most patients with
leukemia and non-Hodgkin’s lymphoma. No
approved therapies target the hallmark of the B
cell, its mIgM, also known as the B-cell receptor
(BCR). Aptamers are small oligonucleotides that
can specifically bind to a wide range of target
molecules and offer some advantages over anti-
bodies as therapeutic agents. Here, we report the
rational engineering of aptamer TD05 into multimeric
forms reactive with the BCR that may be useful in
biomedical applications. Systematic truncation of
TD05 coupled with modification with locked nucleic
acids (LNA) increased conformational stability
and nuclease resistance. Trimeric and tetrameric
versions with optimized polyethyleneglycol (PEG)
linker lengths exhibited high avidity at physiological
temperatures both in vitro and in vivo. Competition
and protease studies showed that the multimeric,
optimized aptamer bound to membrane-associated
human mIgM, but not with soluble IgM in plasma,
allowing the possibility of targeting leukemias
and lymphomas in vivo. The B-cell specificity of the
multivalent aptamer was confirmed on lymphoma
cell lines and fresh clinical leukemia samples. The
chemically engineered aptamers, with significantly
improved kinetic and biochemical features,
unique specificity and desirable pharmacological
properties, may be useful in biomedical applications.
INTRODUCTION
Non-Hodgkin’s lymphomas (NHLs) are the ﬁfth most
common type of cancer in the USA (1). While several
effective chemotherapies and immunotherapies are
available, cures still elude most patients (2). The addition
of more selective strategies with monoclonal antibodies to
cell surface targets such as CD20, CD22 or CD23 has
improved outcomes and three antibodies to CD20 have
been approved by the Food and Drug Administration
(FDA) to treat B-cell NHL (3). However, there are no
approved agents that target the hallmark of the B cell,
the B-cell receptor (membrane Ig: mIgM) or BCR.
Development of an antibody to mIgM is challenging
because the unique epitopes are close to the cell surface
and may be inaccessible to large antibody molecules.
Recent interest in oligonucleotide-based therapeutic
agents such as siRNA or microRNA (4) is based on the
fundamental advantage of automated synthesis and easy
chemical manipulation that allow quality control and
modiﬁcation of function. Technologies that enhance
plasma stability by use of unnatural nucleic acids and
recent studies characterizing the pharmacokinetics of
nucleic acid-based therapeutic agents suggest feasible use
of these agents in vivo (5–7).
DNA aptamers can also be developed into therapeutic
agents. Aptamers are short oligonucleotide sequences that
can speciﬁcally bind to a wide range of target molecules,
such as drugs, proteins and other inorganic or organic
molecules with high afﬁnity and speciﬁcity (8,9).
Aptamer binding is based on the ability of small oligo-
nucleotides (typically 40–100mers) to fold into unique
three-dimensional structures that can interact with a
speciﬁc binding region of the target molecule. Aptamers
have inherent advantages that merit application as thera-
peutic agents (10): (i) the ability to withstand high heat
and denaturants, (ii) rapid chemical synthesis, (iii) small
size (10–20000Da versus 150000Da for antibodies) and
(iv) non-immunogenicity (11). In therapeutic applications,
antibodies are limited by large size and the consequent
inability to easily diffuse extravascularly or to penetrate
large solid tumors (12). Typical monovalent aptamers are
potentially limited by reduced retention times on the
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tion of targets. Aptamer-based bivalent ligands, however,
have been demonstrated to increase afﬁnity and function
compared to the monovalent versions; for example,
bivalent aptamers were used to activate thrombin and T
cells (13–15).
Recently, selection of a high-afﬁnity DNA aptamer
(TD05) reactive with Burkitt’s lymphoma was reported
(16). At 4 C, TD05 binds to an epitope on B-cell surface
mIgM BCR, exclusively expressed on B cells and most
B-cell lymphomas (17). Aptamer TD05 is not useful
in vivo, however, because of its lack of afﬁnity and sta-
bility at physiological temperatures in human plasma.
Moreover, it was not evident that TD05 could reach
target B cells in vivo for diagnostic and therapeutic appli-
cations if the epitope was also present on circulating IgM,
which is found in the plasma at 450–1500mg/l (18).
To address these issues and to produce aptamers with
potential medical applications, we ﬁrst truncated TD05,
and further optimized it by introducing locked nucleic
acids (LNA) to increase nuclease resistance and conform-
ational stability. The construct was additionally re-
designed into bivalent, trivalent and tetravalent scaffolds
in order to improve the afﬁnity, and possibly to create an
agent that could crosslink the BCR, which might have the
biological effect of modulating the cell surface expression
of the BCR, internalizing the complex, or activating or
deactivating signaling pathways (19,20). We report the
rational engineering of multivalent aptamer scaffolds
that show higher thermal and nuclease stability, conform-
ational stability, improved kinetic and biochemical
properties at physiological temperatures.
MATERIALS AND METHODS
Cell lines, Ramos (Burkitt’s lymphoma), Daudi (Burkitt’s
lymphoma), Raji (Burkitt’s lymphoma), Jeko (mantle cell
lymphoma), SKLY-16 (B-cell lymphoma), CRW22R
(Prostate cancer), H5V (Endothelial cells), HCT116
(Colorectal carcinoma), HEK293 (human embryonic
kidney), HeLa (human adenocarcinoma cervical), K562
(leukemia chronic myelogenous), MOLT (acute lympho-
blastic leukemia), SKOV-3 (human adenocarcinoma
ovarian), HL60 (acute myelocytic leukemia), Jurkat
(T lymphocyte) and SKLY-18 (B-cell lymphoma) were
purchased from ATCC except for SKLY16 and 18. All
of the cells were cultured in RPMI 1640 medium supple-
mented with 100U/ml penicillin–streptomycin and 10%
fetal bovine serum (heat-inactivated; Invitrogen).
Clinical samples were obtained from patients at
Memorial Sloan Kettering Cancer Center or from
healthy donors, on IRB approved protocols.
Phosphoramidites including spacer phosphoramidite
18, amino modiﬁer C6-dT, 50-ﬂuorescein phospho-
ramidite, Cy3
TM phosphoramidite, and all the DNA
reagents that are needed for DNA synthesis were
purchased from Glen Research. LNA dT and dC were
purchased from Exiqon, TetVA.8S, L-TetVA.8S were
purchased from Trilink Biotechnologies Inc.
All the DNA oligo sequences were chemically
synthesized attaching a ﬂuorophore at the 50 end using
standard solid phase phosphoramidite chemistry on an
ABI394 DNA synthesizer using either a 0.2mmol or
1mmol scale. The completed DNA sequences were
de-protected. The crude product was puriﬁed using
HPLC (Beckman Coulter System Gold Bioessential 125/
168 diode-array detection instrument) equipped with a
C-18 column (Dyanamax 250 10mm, Varian) using
0.1M TEAA as the mobile phase. The length of each
DNA construct was conﬁrmed using 10%-TBE urea poly-
acrylamide gel electrophoresis. Full-length DNA was
quantiﬁed by measuring the absorbance at 260nm and
absorbance of the corresponding dye at the 50 position
using a Cary Bio-100 UV-Visible spectrophotometer
(Varian). Sequences used in nuclear magnetic resonance
(NMR) experiments were further dialyzed overnight
with 0.5mM NaHPO4 buffer using a MWCO 1000-Da
dialysis bag.
All the in vitro experiments were done using a binding
buffer composed of RPMI 1640 and 4.5g/l glucose
(Sigma-Aldrich) and 5mM MgCl2 for monomers,
20mM MgCl2 for multimers (Sigma-Aldrich), 100mg/l
tRNA (Sigma-Aldrich), 100mg/l single-stranded DNA
(Sigma-Aldrich), 100mg/l BSA (Sigma-Aldrich) and
binding was analyzed using ﬂow cytometry (Acurri C6)
using wash buffer. We used 20mM Mg
+2 for optimal
folding of the aptamer in vitro and 5mM Mg
+2 for experi-
ments in vivo. The binding buffer consists of tRNA and
single-stranded DNA that are capable of scavenging
Mg
+2, thereby reducing the effective concentration of
Mg ions. The concentrations of MgCl2 used did not
show any toxicity towards the cells. Wash buffer
was composed of RPMI1640 with 20mM
MgCl2,0.5% BSA.
Cell binding assays
Afﬁnity of each construct was evaluated by incubating
Ramos cells (2.5 10
5) with a series of ﬂuorescein isothio-
cyanate (FITC)- or Cy3-labeled constructs in a 50mlo f
binding buffer on ice for 45min. Cells were then washed
with 1ml of wash buffer at 4 C and resuspended in 100ml
of wash buffer. The binding of the constructs was
analyzed using ﬂow cytometry by counting 10000 events
for each concentration. As a positive control, a similar
assay was performed using an FITC-labeled anti-IgM
antibody (1mg, Goat anti human, Invitrogen) along with
an isotype control (1mg, Goat anti mouse IgG2a,
Invitrogen). Binding at respective concentrations and
absolute ﬂuorescence intensity difference was used for
the binding curves. When calculating the relative binding
constant, binding curves were ﬁtted with median ﬂuores-
cence intensity observed for each histogram and observed
Bmax/2 was used as the binding constant. Control
random sequences with each ﬂuorophore were synthesized
separately and used to compare nonspeciﬁc background
binding. Assays were done using ﬂow cytometry in which
each data point reported corresponds to the median of
10000 counted events. Investigation of the multimeric
aptamer binding with clinical chronic lymphocytic
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(PBMC) samples were done by incubating FITC-labeled
multimeric aptamer (0.5mM) or FITC-labeled random
control along with APC labeled anti-CD19 (0.5mg),
Cy5.5-labeled anti-CD45 (50ng) with 1 10
6 cells
(cultured or CLL) on ice. After 45min, the cells were
washed with wash buffer and analyzed for binding using
ﬂow cytometry. Investigation of aptamer interaction of
mIgM was done in 20% or 50% or 100% human serum
supplemented with 20mM MgCl2 for multimeric
aptamers, or 5mM MgCl2 for monomeric aptamers
using a similar protocol as above.
Nuclease stability
Aliquots of 50pmol of multivalent constructs labeled with
a ﬂuorophore were incubated at 37 C in a ﬁnal volume of
20ml in human serum and in 20ul of phosphate-buffered
saline (PBS) buffer for 0, 0.5 1, 2, 4, 6, 8, 10, 24h. At
the end of each time point, the reactions were terminated
by adding 20ml 2X nucleic acid loading buffer (Bio-Rad)
and stored in  80 C. Full-length and digested DNA
were analyzed by 10%-TBE urea polyacrylamide gel
electrophoresis and ﬂuorescence was quantiﬁed using
FUJI FILM multi gauge V2.2 software. The average
half-lives were calculated with Prism V ﬁtting to exponen-
tial decay.
Trypsin digestion experiments
Cold PBS washed 5 10
5 Ramos cells were incubated with
1mg/ml trypsin (TPCK treated, Sigma T1426) in 500mlo f
0.05% Trypsin EDTA 1X in HBSS (Cellgro 25-052-Cl) for
40min at 37 C. The incubation time was optimized by
initial pilot experiments with varying incubation times
from 10 to 40min. The trypsin cleavage site is masked
(17); therefore, longer incubation times were needed to
observe optimal cleavage. In earlier time points, we did
not observe signiﬁcant reduction in binding with cells by
either the aptamer or anti-IgM antibody. After incuba-
tion, cells were pelleted, washed with cold PBS, and
aliquots were incubated with 1mM of TD05.1, 1mMo f
Random DNA, anti-CD20 and FITC-labeled goat
anti-human IgM antibody (1mg) along with an isotype
control (1mg, Goat anti mouse IgG2a, Invitrogen) for
45min at 4 C. Then the cells were washed and resus-
pended in cold PBS containing 20mM MgCl2 and 0.5%
BSA, and the binding was detected using ﬂow cytometry
(Becton Dickinson FacsCalibur 2002 model).
In vivo binding assay
Female athymic nude mice, 4–8 weeks of age (Taconic,
Germantown, NY) were inoculated i.p. with 7 10
6
Ramos cells in 0.5ml of saline. After 10min, 0.5ml of a
1mM solution of TetVA.8S or random aptamer in saline
was introduced i.p. Animals were sacriﬁced after 1h and
the intraperitoneal cavity was ﬂushed by 10ml PBS and
collected the cells. The cells were divided into three
aliquots and incubated with binding buffer supplemented
with (i) 0.5% BSA, (ii) 10mg/ml of anti-CD19 and
(iii) 200mg/ml of anti-IgM antibody for 30min in ice.
The cells were then washed using 1ml of washing buffer
and binding of the aptamer and the antibody was
investigated using ﬂow cytometry counting 10000 events
(Becton Dickinson FacsCalibur 2002 model). Prior to the
experiment, animals were housed in ﬁlter-top cages and
provided with sterile food, water and bedding. Animal
protocols were approved by the Animal Care and Use
Committee at Memorial Sloan-Kettering Cancer Center.
RESULTS
Modiﬁcation of TD05
Truncation. TD05 was unstable at physiological condi-
tions and unable to bind its target on Ramos B-cell
lymphoma (Figure S1 and S2). The predicted secondary
structure of the TD05 using m-fold was a ‘hairpin’ struc-
ture (Figure 1 and Supplementary Figure S1; m-fold is a
software application used to predict secondary structure
of DNA) (21). Structural studies of a stem identical to the
palindromic region of TD05 and full-length TD05
(Supplementary Figure S3) using NMR showed predom-
inant formation of the stem at 37 C. Broadening of the
peaks with decreasing temperature suggested the loss of
homogeneity of the secondary structure. At lower tem-
peratures therefore, TD05 might be forming multiple
folds that lead to a more heterogeneous mixture, with
only a few structures that ﬁt the target epitope.
The original TD05 aptamer consisted of 48nt and a
later truncated version of 44nt was reported by
removing bases from the ends (16,17,22). Because
afﬁnity was retained in the truncated version, in which
the stem was shortened, it is likely that bases in the
central loop region of the aptamer play the most import-
ant role in binding. We investigated the possibility of
further truncating TD05 with the aim of increasing the
afﬁnity by stabilizing the secondary structure of TD05.
We truncated the bases starting from the 30 and 50
region (Figure 1). Shorter versions, e.g. TD05.1, showed
higher afﬁnity than the original version even after 10nt
were removed (Table 1). We speculated that the reduction
of the length of the TD05 stem could be leading to a
population with more stable secondary structure contain-
ing a favorable fold that better ﬁt the protein-binding site.
In addition, shorter sequences could also be synthesized
with higher yields and lower costs, which was particularly
important for a strategy in which multimeric aptamers
were planned.
LNA incorporation. The incorporation of LNA bases to a
stem region of a stem–loop structure has been shown to
increase the melting temperature, nuclease stability and
overall stability of the secondary structure of aptamers
(23–25).ThisismainlybecauseLNAmodiﬁedoligonucleo-
tides, derived from the constrained sugar moiety with
30-endo conformation resulting from the methylene link
between the 20 oxygen and 40 carbon of the ribose ring
exhibit increased afﬁnity toward their cDNA (26). We
postulated that the further stabilization of the stem by
inclusion of LNA would also increase the in vivo stability
of the secondary and tertiary structures. We incorporated
LNA into the stem region of TD05.1 in three different
2460 Nucleic Acids Research, 2011,Vol.39, No. 6combinations by substituting purines and pyrimidines
(TD05.16), pyrimidines only (TD05.17), and purines only
(TD05.18) (Table 1). The low binding of TD05.18 suggests
LNA substitution of purines A1G2G3A4 had a profound
effect on the secondary and tertiary structure (Table 1).
Substitution of the pyrimidines T32C33C34T35 with
LNA further increased the dissociation constant,
indicating that these bases may not be involved in
binding, but may aid in stabilizing the stem region.
Attempts to introduce nuclease-resistant 20-OMe bases
into the loop region impaired binding, yielding a Bmax/2
values higher than the TD05.1, suggesting that the loop
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Figure 1. Optimization of monomeric and multimeric scaffolds and their Bmax/2 (Kd0)a t3 7  C (top number) and at 4 C (bottom number).
(A) original TD05 sequence. (B) Truncated TD05.1. (C) LNA modiﬁed TD05.1 (TD05.17). (D) Bivalent TD05.17 (L-BVA.8S). (E) Trivalent
TD05.17 (L-TVA.8S). (F) Tetravalent TD05.17 (L-TetVA.8S). The constructs were synthesized with PEG at the 50- and 30-ends; Cy3 or FITC
was added at the 50-end. Red=LNA bases.
Table 1. Modiﬁcations of TD05 alter binding at 4 C
Name Figure 1
structure
Deletions/changes Bmax/2 at
4 C (nM)
TD05 A ACCGTGGAGGATAGTTCGGTGGCTGTTCAG GGTCTCCTCCACGGT 359
TD05.7 XXCGTGGAGGATAGTTCGGTGGCTTCAGGGTCTCCTCCCGXX 148
TD05.1 B XXXXXAGGAG GATAGTTCGGTG GCTGTTCAG GGTCTCCTCCTXXXXX 53
TD05.10 GGAGGANAGTTCGGTGGCTGTTCAGGGTCTCCTCC >1000
TD05.11 GGAGGATAGTTCGGTNGCTGTTCAGGGTCTCCTCC >1000
TD05.12 GGAGGATAGTTCGGTGGCTGTNCAGGGTCTCCTCC >1000
TD05.16 +A+G+G +A GGATAGTTCGGTGGCTGTTCAGGGTCTCC+T+C+C+T 368
TD05.17 C AGGAGGATAGTTCGGTGGCTGTTCAGGGTCTCC+T+C+C+T 43
TD05.18 +A+G+G+A GGATAGTTCGGTGGCTGTTCAGGGTCTCCTCCT 819
+N =LNA; italic, bold N=2 0OMe substituted nucleotides; X=deletions.
Nucleic Acids Research,2011, Vol.39, No. 6 2461region cannot be modiﬁed with nuclease-resistant 20OMe
(Table 1). Difﬁculties in introducing the modiﬁed bases
within an aptamer sequence have been reported before,
and the loss of binding is probably due to changes of the
favorable fold of the aptamer (24).
Multivalent TD05.1 constructs and optimization of the
linker lengths
One strategy to decrease the dissociation rates is to
increase local concentration by multimerization of the
ligand. The resulting decreased dissociation rates might
also be useful in vivo. In therapeutic applications, lower
retention times would likely decrease the therapeutic
index. Therefore, based on the improved afﬁnity and sta-
bility of TD05.1, we designed multivalent analogs with
PEG linkers in an attempt to increase afﬁnity at physio-
logical temperatures (Figure 1).
Although several approaches to multivalent designs are
possible, we focused on linear molecular assembly of
TD05.1 using poly-ethylene-glycol (PEG) linkers,
because this would also more likely allow cross-linking
of BCR on the cell surface, which might in turn lead to
internalization of the complex for delivery of cytotoxic
cargo or to modulation of BCR signal transduction
pathways. PEG phosphoramidite is commercially avail-
able for solid-state synthesis of multivalent analogs, so
this linker was chosen to construct various linear multiva-
lent aptamer forms. Linker length between aptamer
binding sites was optimized to avoid steric hindrance
and to promote binding. Most naturally occurring
antibodies are bivalent; therefore, ﬁrst, we designed a
bivalent (BV) TD05.1. In order to mimic dimensions of
an antibody and provide appropriate spatial ﬂexibility to
promote binding of a bivalent aptamer, linker lengths of 6,
8 and 12 (lengths correspond to 12.6, 16.8 and 25.2nm)
were designed and their binding to Ramos cells was
evaluated using ﬂow cytometery. The PEG spacer was
 2.1nm in length, which has been reported elsewhere
(13), and this approximation was assumed for this study.
Observed binding for bivalent analogs was similar to
monomeric TD05.1 at 37 C; however, at 4 C BV.8S
showed slightly higher binding than BV.6S and BV.12S,
indicating that bivalent design with eight linkers, which
corresponds to 16.8nm, is more favorable for the
bivalent design. Therefore, we evaluated the linker
length of 16.8nm on the bivalent version of TD05.17
(i.e. L-BVA.8S), assuming that increased structural stabil-
ity of the stem along with the dimerization might play
additive roles in increasing avidity. L-BVA.8S did show
a signiﬁcant increase in the Bmax/2 at 37 C (Table 2).
However, this increment was likely still inadequate for
in vivo applications. This suggested that increasing
valency by two, alone, was not enough to substantially
increase avidity. Subsequently, eight linkers were used to
design trivalent (TVA.8S) and tetravalent (TetVA.8S)
TD05.1-based aptamers to further investigate the
binding avidity (Figure 1).
At 37 C, a trivalent aptamer (TVA.8S) using eight
linkers between each monomeric aptamer, showed
increased binding (Table 2). In order to determine
whether the improved TVA.8S binding is a result of inter-
action of each of the three aptamers with epitopes versus
an improvement based on either length or geometry, we
designed a hetero-trimeric analog of the homo-trimeric
TD05.1 in which the loop of the central monomer was
randomized and linked to distal monomers using eight
PEG units (TVSR). At 4 C, the binding of the heteromeric
TVSR was three to four times lower than that of the
TVA.8S at a ﬁxed concentration, suggesting that the
internal monomer in the trivalent aptamer plays a role
in increasing the avidity of the trimeric molecular
assembly, either by altering structure or by adding an add-
itional binding site. The decrease in the binding of TVSR
also might be due to intramolecular interactions of the
randomized region with the distal aptamers. We also
designed dimers with 16 and 20 linkers to generate a
dimeric version with a length similar to the TVA.8S.
Binding at 4 C of the long dimer BVA.20S was less than
the TVA.8S, suggesting that the longer linkers may be
leading to unfavorable conformations. Alternatively, the
longer length between the two monomers could make the
dimer spatially unsuitable for binding. BVA.16S showed a
Bmax/2 of 2030nM at 37 C; however, afﬁnity of the
dimer was not as high as the corresponding trivalent
design. In addition, the tetravalent analog of TD05.1
showed no signiﬁcant increment in binding. This might
Table 2. Optimization of linker length and linear assembly of TD05.1
Name Structure in
Figure 1
Sequence Bmax/2@37 C (nM)
TD05.1 B AGGAG GATAGTTCGGTG GCTGTTCAG GGTCTCCTCCT >10000
BV.6S TD05.1 -(sp18)6 - TD05.1 >10000
BV.8S TD05.1 -(sp18)8 - TD05.1 >10000
BV.12S TD05.1 -(sp18)12 - TD05.1 >10000
BV.16S TD05.1 -(sp18)16- TD05.1 2030
TVA.8S TD05.1 -(sp18)8 - TD05.1 -(sp18)8 - TD05.1 490
TetVA.8S TD05.1 -(sp18)8 - TD05.1 -(sp18)8 - TD05.1-(sp18)8 - TD05.1 425
TD05.17 C AGGAGGATAGTTCGGTGGCTGTTCAGGGTCTCC+T+C+C+T >10000
L-BVA.8S D FITC-sp18-TD05.17-(sp18)8 - TD05.17-sp18 6222
L-TVA.8S E Cy3-Sp18-TD05.17 -(sp18)8 - TD05.17 -(sp18)8 - TD05.17-Sp18 256
L-TetVA.8S F Cy3-sp18-TD05.17-(sp18)8-TD05.17-(sp18)8-TD05.17-(sp18)8-TD05.17-sp18 272
+N =LNA; Sp18=spacer 18.
2462 Nucleic Acids Research, 2011,Vol.39, No. 6be due to the density of receptors on the cell surface
limiting the increase in the dissociation constant.
Alternatively, the binding interaction might be linker in-
dependent beyond 16.8nm.
To further investigate the improved afﬁnity, the tri- and
tetra- valent scaffolds were re-synthesized using TD05.17
(containing LNA) as the monomer. The afﬁnity of each
construct was increased  2-fold suggesting that the locked
version of the aptamer aided in stabilizing the conform-
ation of the stem (Table 2). The LNA-modiﬁed multimeric
versions were further modiﬁed with PEG spacers at the 30
and 50 ends to avoid 30 and 50exonuclease activity. The
original unmodiﬁed TD05 showed a half-life of <1h,
whereas L-TVA.8S showed an estimated half-life of
8.75h, demonstrating that the modiﬁcations introduced
for TVA.8S signiﬁcantly enhanced the nuclease stability
in serum (Figure 2). L-BVA.8S showed a half-life of 7.87h
suggesting that multimerization and PEGylation contrib-
utes to increase stability (Supplementary Figure S4).
Cell speciﬁcity
The speciﬁcity of the divalent scaffold for B cells and
B-cell lymphoma was investigated using fresh mononu-
clear cells from healthy donors, patients with chronic
lymphocytic leukemia, cultured B-cell lymphoma cells ex-
pressing or not expressing mIgM and cultured non-B-cell
cancers, using FITC-labeled L-BVA.8S and quantiﬁed
using ﬂow cytometry. An analogous randomized
aptamer sequence linked with eight PEG units was used
as the isotype control. There was generally little
nonspeciﬁc binding to cells not expressing surface
mIgM, whereas B-cell lymphoma cell lines expressing
mIgM and B cells gated from clinical samples were
usually positive (Table 3). Interestingly, B cells obtained
from healthy individuals only sometimes stained positively
for L-BVA.8S aptamer. CD3-positive T cells rarely
bound to this aptamer, further conﬁrming the speciﬁcity
(Figure 3). However, several of the mIgM expressing
B-cell lymphoma cell lines and clinical samples did not
bind the aptamers (Table 3), perhaps because the
epitope was masked or the expression levels were low,
suggesting that while speciﬁcity was high, sensitivity was
lower (Table 3). In addition, the TVA.8S displayed poor
binding to fresh samples as compared to the L-BVA.8S,
although competition analyses (data not shown)
demonstrated that both bivalent and trivalent aptamers
competed for binding of the monomeric aptamer to
Ramos. These data suggest that subtle differences in the
local environment of the epitope may be affecting the
ability of the different-sized aptamers to bind to fresh
samples.
As previously reported, the monomeric aptamer TD05
competed with the anti-IGHM (anti-Immunoglobin
Heavy Mu Chain) antibody for binding to Ramos cells,
indicating that the aptamer binding site was located on or
near the IgM heavy chain (17). We determined whether
the multimeric aptamer could retain binding in the
presence of the anti-IGHM antibody. In the presence of
anti-IgM antibody, ﬂuorescence shifts to the background
level for the multimeric aptamer scaffolds, which
demonstrated that anti-IgM competes with the aptamer
Table 3. Analysis
a of speciﬁcity of dimeric aptamers with cultured
cells and clinical samples
Cell line Cell type Bivalent
aptamer
(structure D)
staining
Ramos B-Lymphoma, Burkitt’s IgM+ +
SKLY-16 B-lymphoma IgM+ +
Daudi
b B-lymphoma IgM+ +
Raji B-lymphoma, Burkitt’s IgM+  
Jeko Mantle cell lymphoma (B)  
Bjab B-Lymphoid leukemia  
SKLY 18 B-lymphoma IgM-  
AL67 Mouse ﬁbroblast  
CRW22R Prostate cancer  
H5V Endothelial cell lines (heart)  
HCT116 Carcinoma colon  
HEK293 Human embryonic kidney  
HeLa Human adenocarcinoma (cervical)  
K-562 Leukemia, chronic myelogenous  
MOLT T-Leukemia, acute lymphoblastic  
SKOV-3 Ovarian  
HL60 Leukemia, acute promyelocytic  
Jurkat T-Leukemia, acute  
CML
c Clinical sample  
CLL
d Clinical samples +
HCL
e Clinical sample +
Normal B cells
f Donors +/ 
Normal T cells
g Donors  
aMedian of the ﬂuorescence intensity of FITC-labeled aptamer/ median
of the ﬂuorescence intensity of FITC-labeled random sequence  2.0
equals positive (+).
Experiments were done at 4 C.
bVariable binding to Daudi was observed.
cOne sample. CML is chronic myeloid leukemia, a non-B-cell
neoplasm.
dFourteen samples; CLL is B-chronic lymphocytic leukemia; in two of
the samples, the gated CD19-negative population showed positive
signal with the aptamer
eOne sample. HCL is hairy cell leukemia, a B-cell neoplasm.
fNine samples; ﬁve of the normal B-cell samples were negative and
three were only weakly positive.
gTwenty-three samples; a small subpopulation of one of the normal
T-cell samples was weakly positive.
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Figure 2. Analysis of nuclease stability of L-TVA.8S in human serum
at physiological temperature. Aptamers were separated using
poly-acrylamide gel electrophoresis and ﬂuorescence intensity of
full-length DNA/area (mm
2) was plotted as a function of time (hours).
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multimerization does not change the speciﬁcity. These
data in sum lead to the conclusion that the multimeric
aptamer interaction is selective for an epitope on the
mIgM itself.
Aptamers recognize membrane bound mIgM, but not
soluble IgM
Soluble Ig is found in high concentrations in plasma.
Hence, one of the major drawbacks in using anti-Ig
antibodies as therapeutic vehicles for the treatment of
lymphoma is that these antibodies interact with the
soluble Ig in serum, leading to immune complexes that
are cleared. Thus, binding is signiﬁcantly limited at
tumor targets. mIgM contains an additional 41 amino
acids that are not present in the soluble IgM, which are
present in or near the membrane. Approximately 15 of
these amino acids are found extracellularly (27–29).
If the aptamer binds only to the mIgM, we postulated
that these additional extracellular amino acids might play
a signiﬁcant role in deﬁning the epitope speciﬁcity.
Interestingly, a trypsin cleavage site is present at amino
acid 430, at the border of the sequence difference between
soluble and membrane bound mIgM (28). Thus, the
membrane-associated sequences proximal to amino acid
430 are present only in the membrane-bound form.
Trypsinization to cleave off the domains of the
membrane bound mIgM distal to this site left only the
most proximal region present on the cell membrane. At
high concentrations of trypsin, there is a dramatic reduc-
tion in binding of goat anti-IgM antibody with Ramos
cells but TD05.1 does not change its binding signiﬁcantly
(Figure 4). These data indicate that TD05.1 predominately
interacts with the unique extra amino acid sequences of
mIgM and not with the distal portions of IgM that are
present in soluble, circulating IgM. CD20 is a
non-glycolysated phosphoprotein expressed on early and
mature normal B cells at developmental stages that are the
source of a variety of B-cell neoplasms, including B-cell
NHL and CLL (30). Therefore, CD20 was used as a
positive control for the enzymatic cleaving experiment.
We further investigated whether the epitope of the
aptamer was restricted to the surface mIgM by measuring
Figure 3. Binding of LNA-modiﬁed bivalent aptamer binding with B cells and T cells. (Upper left) Bivalent aptamer binding to CD19-positive B
cells. (Upper right) Bivalent aptamer does not bind to CD3-positive, CD19-negative cells. (Lower left) Bivalent randomized control aptamer does not
bind to CD19-positive cells. (Lower right) Bivalent randomized aptamer does not bind to CD3-positive cells.
2464 Nucleic Acids Research, 2011,Vol.39, No. 6the binding of TD05.1 in the presence of soluble IgM. The
aptamers were incubated with Ramos cells in the presence
of a large excess of puriﬁed soluble IgM in binding
buffer or in the presence of 20% human serum (containing
 90–300mg/l IgM). An antibody speciﬁc for IgM heavy
chain showed a dramatic reduction in binding to the cell
membrane when free soluble pentameric IgM was present
in the reaction (Figure 5A). The aptamer binding was un-
affected (Figure 5B) showing that the epitope of the
aptamer was restricted to cell membrane bound IgM.
This speciﬁcity is critical to the feasibility of using this
aptamer as a targeting vehicle in vivo. In addition to the
monovalent aptamer, TetVA.8S was also assayed for its
ability to speciﬁcally recognize the ‘membrane–bound’
heavy chain of the IgM when excess amount of soluble
IgM (50%) was present in the binding buffer. The
TetVA.8S binding to Ramos cells was unaffected when
excess soluble IgM was present; however, a decrease in
binding was observed in 50% human serum (Figure 5C).
This decrease might be due to nonspeciﬁc interactions
with serum proteins other than soluble IgM which
would decrease the effective concentration of the
TetVA.8S.
The trypsin cleavage experiments and cross-blocking
with anti-IgM are most consistent with the aptamer
binding epitope localizing to a segment of the mIgM
unique to the proximal membrane portion of the
molecule. However, these data could also be explained
by conformational changes in the soluble IgM that hide
the epitope at its proximal terminus. It is also possible that
accessory molecules in the vicinity of the epitope on the
cell surface allow for binding of the aptamer.
In vivo binding of TetVA.8S with Ramos cells
The TetVA.8S was administered i.p. into mice bearing
Ramos cells in their intraperitoneal cavities to investigate
binding in vivo. TetVA.8S selectively recognized Ramos
cells in the intraperitoneal cavity of live mice, suggesting
the feasibility of using this aptamer as a therapeutic car-
rier or agent (compare Figure 6A and D). Flow cytometry
conﬁrmed the speciﬁcity of the TetVA.8S binding
to mIgM expressing B cells in vivo using excess anti-IgM
antibody and anti-CD19 antibody as controls
(Figure 6B–E and F). Although the intraperitoneal
model does not exactly resemble intravascular model,
this experiment demonstrates at physiological conditions
in a live mouse that the multivalent construct of the
aptamer TD05 speciﬁcally recognizes its target epitope
on Ramos cells.
DISCUSSION
The BCR is a unique feature of cells of B-cell lineage,
including most B-cell NHL. Therefore, the BCR is an at-
tractive therapeutic target for lymphoma or disorders of
the immune system. Approaches to this target, however,
have been limited by the lack of an appropriate reagent
that could selectively bind to an epitope on the BCR that
was not also present on the circulating, soluble IgM,
which is found at high concentrations in human plasma.
One difﬁculty in identifying an antibody-based reagent to
the mIgM may be that the unique epitopes near the cell
surface are inaccessible to large antibody molecules. As
the activation of the BCR in B cells is directly related to
B-cell growth and function, the multivalent forms of
agents that speciﬁcally bind to the BCR, such as the
aptamers described here, might be useful not only as
vehicles for therapeutic cargo, but also as modulators of
B-cell function. Therefore, aptamers might have thera-
peutic applications in autoimmune diseases, immune deﬁ-
ciency diseases, in immunosuppression or in vaccination
strategies.
A previously described aptamer, TD05, appeared to
bind to the mIgM, but was not able to bind its target
Figure 4. Binding of TD05.1 to mIgM after trypsin treatment. Cells were treated with trypsin for 40min and binding of FITC-labeled (A) TD05.1,
(B) anti-CD20 and (C) anti-IgM antibody was evaluated and compared with untreated control.
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Figure 6. Binding of TetVA.8S with Ramos cells in the intraperitoneal cavity. 1mM of either TetVA.8S or random DNA in saline was injected into
intraperitoneal cavity. Ramos cells were withdrawn from the intraperitoneal cavity and co-stained with control (BSA alone), cy5-labeled anti-IgM
antibody or APC-labeled anti-CD19. (A) FITC-random sequence injected i.p. (ex vivo BSA control). (B) FITC-random sequence injected i.p.;
co-stained with anti-CD19. (C) FITC-random injected i.p.; co-stained with anti-IgM. (D) FITC-TetVA.8S injected i.p. (ex vivo BSA control). (E)
FITC-TetVA.8S injected i.p.; co-stained with anti-CD19, F: FITC-TetVA.8S injected i.p.; co-stained with cy-5-anti-IgM.
ABC
Figure 5. Binding of aptamer in the presence of soluble IgM or human serum. The FITC-labeled monomeric and tetrameric aptamer was incubated
with Ramos cells in the presence of soluble IgM/human serum for 30min, and subsequently washed and binding was analyzed using ﬂow cytometry.
(A) Positive control showing blocking of anti-IgM by serum or soluble IgM. (B) Monomeric aptamer binding is not affected when serum or excess
soluble IgM is present. (C) Tetrameric aptamer binding is not signiﬁcantly affected when serum and excess soluble IgM is present.
2466 Nucleic Acids Research, 2011,Vol.39, No. 6under physiologic conditions, nor was its selectivity for the
mIgM versus soluble IgM known. So far, attempts to
develop antibodies for mIgM have been limited due to
interactions with the soluble versions (31). The optimized
aptamer described here is unique due to its interaction
with the mIgM but not with soluble IgM, signiﬁcantly
increasing the potential therapeutic application as a
BCR cross-linker or as a drug delivery agent.
An important goal our study intended to use was
rational engineering to prepare a new aptamer, derived
from TD05, which can selectively recognize mIgM under
physiological conditions. Here, we aimed at improving
aptamer TD05 to make it suitable for in vivo applications
by addressing issues pertaining to speciﬁcity, afﬁnity and
in vivo stability. First, truncation of the aptamer TD05
resulted in improved binding, presumably by creating a
compact fold which better ﬁt with the epitope. Second,
in order to increase the structural stability, we introduced
LNA bases in a favorable combination by substituting
pyrimidines on the stem. The substitution of the purines
in the stem has impaired binding, suggesting that the
binding site of the aptamer is affected by these residues.
However, the pyrimidine substitution stabilized the struc-
ture leading to a higher-afﬁnity constant than the original
structure. As LNAs are resistant to nuclease digestion,
LNA modiﬁcation of the stem not only stabilizes the sec-
ondary structure by forming a strong stem, but will also
increase the stability against nuclease attack. The use of
LNA to increase the aptamer stability has been
demonstrated before. For example, LNA modiﬁcation in
the stem region of the anti-tenascin and sgc8 aptamer
showed increased thermal and nuclease stability (22,25).
Third, PEGylation of the aptamer ends was employed to
improve stability and pharmacologic performance.
Fourth, the multimerization of monomer signiﬁcantly
increase the avidity at physiological temperature.
Generation of multimeric ligands for targeted delivery
and imaging is well established (32). For example, Fab
fragments have been chemically engineered to increase
their avidity (33), and RGD multimerization has been
introduced to increase the avidity of the monomeric
RGD ligand (34). In addition, multimeric agents such as
mAb and various nano-materials such as nanoparticles,
nanotubes, dendrimers and biodegradable polymers are
being used as diagnostic and therapeutic platforms (35).
Interaction of the multivalent ligands with its target can be
explained by increased effective concentrations of the
ligand at the target site without losing the entropic
penalty after initial ligand–receptor contact. The subse-
quent interaction of the unbound ligand becomes exclu-
sively intramolecular, contributing to the increase in the
afﬁnity by decreasing the dissociation rates.
Although larger-sized nano-materials achieve multiva-
lency, these constructs can be limited due to poor pharma-
cological properties (36). On the other hand, the linear
assembly of small aptamers to synthesize multivalent scaf-
folds has been shown to improve therapeutic properties.
For example, the linear assembly of thrombin aptamers
has been shown to enhance clotting function compared to
monomeric forms (12). Here, we demonstrated, using a
linear assembly, a novel multimeric scaffold with increased
avidity. These constructs were readily synthesized using
PEG phosphoramidite and automated DNA synthesis to
synthesize the multivalent scaffold. The direct synthesis
minimized tedious and low yield bio-conjugation reactions
and poly-dispersed products. The use of long ﬂexible
linkers aided in promoting the proper conformation and
avoided loss of binding due to steric hindrance.
The design of a multivalent scaffold for multiple targets
is often challenging, due to complexity of the binding
patterns. Here, the binding of low-valency scaffolds
mainly depends on the protein density on the cell
surface. The dependence on the cell surface density on
binding is problematic for the optimization of the linker
lengths. We found that linker lengths from 12.6 to
25.2nM did not show a signiﬁcant difference in the
binding constant at 4 C, which may be due to different
patterns of binding in which the binding of the ligands on
either one site or in two different sites in two different
proteins can accommodate the aptamer. The changes of
the avidity at 37 C are more signiﬁcant with increasing
valency. While the avidity increased with increased
valency, the nature of the interactions with variable
linkers will likely vary with mIgM density on the
membrane; thus, a direct comparison of aptamers of
different valency for afﬁnities is difﬁcult. The combination
of truncation, LNA modiﬁcation and multimerization has
shown additive effects in making the avidity of the tri- and
tetrameric scaffolds more than 40-fold higher than the
corresponding original monomeric aptamer.
The observed lack of binding of the original aptamer
TD05 at 37 C may be due to changes of the aptamer
structure with increasing temperature. We predict that
the bi-loop structure (Supplementary Figure S1) instead
of a stem–loop region in TD05 melts with increasing tem-
perature, yielding a low-afﬁnity structure B at physiologic-
al temperatures that cannot compete with the thermal
instability, resulting in dissociation of the complex.
Moreover, it has been reported that, the lateral angle of
the mIgM in the membrane changes with temperature due
to changes of the hydrocarbon structure of the membrane
of B lymphocytes (37). As the nature of the aptamer–
epitope interaction is nonlinear, the aforementioned
changes in both aptamer and the membrane of the
lymphocytic cells with temperature might negatively
affect the complex, leading to dissociation.
The use of DNA aptamers as therapeutic carriers may be
effective for several reasons. The small size of the aptamers
should yield desirable pharmacokinetic properties,
allowing higher signal to background ratio from more
rapid penetration to extra-vasculature tumor sites, as well
as more rapid clearance. The molecular weights of the
aptamers described are 52kDa for the tetravalent
aptamer and 39kDa for the trivalent aptamer, which is
below the estimated molecular weight cutoff for kidney
clearance. Rapid clearance may be critical to keeping
toxicity low when using these aptamers as radiologic or
chemotherapeutic drug delivery agents.
A key step in increasing the selectivity of current thera-
peutic approaches is the development of novel molecular
constructs that target speciﬁc epitopes expressed in
diseased cells. The B-cell receptor, which is the cell
Nucleic Acids Research,2011, Vol.39, No. 6 2467membrane Ig and the hallmark of the B cell, is an attractive
target for therapeutic regulation of normal and neoplastic
B-cell function. In addition, the BCR may also serve as a
target for directed cytotoxicity, for example, via a ligand or
an antibody for example. However, there are no approved
antibody agents that target the BCR, mainly due to inter-
ference by the large quantities of circulating forms of
secreted Ig in the plasma. In conclusion, here we report
the development of an LNA-stabilized multimeric DNA
aptamer that speciﬁcally binds to the membrane IgM
(BCR) on neoplastic B cells, possibly on the unique 15 aa
region expressed onmIgM near thecell surface. The lack of
sensitivity of binding to all B cells that express the mIgM,
and the differences in binding by the different sized
aptamers, suggest that there may be structures in the
local environment near the epitope that affect binding.
Rational chemical engineering was used to design the
multimeric versions, including (i) the linear assembly of
the monomeric version using PEG linkers—linear
assembly allowed the use of automated synthesis,
eliminating the bio-conjugation procedures typically used
in developing multivalent constructs; (ii) systematic trun-
cation of the aptamer coupled with (iii) modiﬁcation with
LNA to increase conformational stability and nuclease
resistance: (iv) dimeric, trimeric and tetrameric versions
with (v) optimized polyethyleneglycol (PEG) linker
lengths to yield high avidity at physiological temperatures
both in vitro and in vivo. So far, to our knowledge there are
no reports of a molecule that targets the mIgM in BCR, at
physiological temperatures.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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